![Alan Liddle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alan Liddle
Direktor/Vorstandsmitglied bei
HaemaLogiX Pty Ltd.
Profil
Alan Liddle is the founder of Immune System Therapeutics Ltd. He is currently a Non-Executive Director at HaemaLogiX Pty Ltd. Mr. Liddle previously worked as a Non-Executive Director at Wallace Absolute Return Ltd. and Wallace Funds Management Pty Ltd. He also served as a Non-Executive Director at Minomic International Ltd. from 2012 to 2018.
Aktive Positionen von Alan Liddle
| Unternehmen | Position | Beginn |
|---|---|---|
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology Develops immunotherapies for blood cancers and B cell disorders | Direktor/Vorstandsmitglied | 01.07.2013 |
Ehemalige bekannte Positionen von Alan Liddle
| Unternehmen | Position | Ende |
|---|---|---|
Minomic International Ltd.
 Minomic International Ltd. BiotechnologyHealth Technology Develops diagnostic and imaging products for prostate cancer and diabetes | Direktor/Vorstandsmitglied | 01.06.2018 |
Wallace Funds Management Pty Ltd.
 Wallace Funds Management Pty Ltd. Investment ManagersFinance WFML primarily invests in companies on the S&P/ASX 200 index, bills of exchange, other negotiable investments, debentures and other permitted investments with prime focus on ASX listed entities. The firm aims to exploit perceived pricing discrepancies in markets by buying securities they believe are undervalued and selling securities they believe are overvalued.^In order to reduce market risk the firm maintains a diversified portfolio in which investments are spread over a range of industry sectors and the value of the bought and sold securities is approximately equal. The firm concentrates on absolute returns and preservation of capital. WFML identifies mispriced assets via fundamental and quantitative research processes, which consider elements such as earnings, yield, share price analysis, money flows, management, and valuation. | Direktor/Vorstandsmitglied | 25.03.2009 |
Immune System Therapeutics Ltd.
 Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Gründer | - |
Wallace Absolute Return Ltd. (Top 20 Holdings)
 Wallace Absolute Return Ltd. (Top 20 Holdings) Investment Trusts/Mutual FundsMiscellaneous Closed-End Investment Fund/Investment Trust | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
7
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Wallace Absolute Return Ltd. (Top 20 Holdings)
Wallace Absolute Return Ltd. (Top 20 Holdings) Investment Trusts/Mutual FundsMiscellaneous Closed-End Investment Fund/Investment Trust | Miscellaneous |
Wallace Funds Management Pty Ltd.
Wallace Funds Management Pty Ltd. Investment ManagersFinance WFML primarily invests in companies on the S&P/ASX 200 index, bills of exchange, other negotiable investments, debentures and other permitted investments with prime focus on ASX listed entities. The firm aims to exploit perceived pricing discrepancies in markets by buying securities they believe are undervalued and selling securities they believe are overvalued.^In order to reduce market risk the firm maintains a diversified portfolio in which investments are spread over a range of industry sectors and the value of the bought and sold securities is approximately equal. The firm concentrates on absolute returns and preservation of capital. WFML identifies mispriced assets via fundamental and quantitative research processes, which consider elements such as earnings, yield, share price analysis, money flows, management, and valuation. | Finance |
Minomic International Ltd.
Minomic International Ltd. BiotechnologyHealth Technology Develops diagnostic and imaging products for prostate cancer and diabetes | Health Technology |
Immune System Therapeutics Ltd.
Immune System Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Immune System Therapeutics Ltd. engages in the development and commercialization of monoclonal antibodies to treat human blood cancers. The company was founded by Alan Liddle and Rosanne Dunn and is headquartered in Ultimo, Australia. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology Develops immunotherapies for blood cancers and B cell disorders | Health Technology |
